• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Generics May Improve Adherence in Breast Cancer Patients, Study Finds

Article

The study, published in the Journal of the National Cancer Institute, found that out-of-pocket costs influenced adherence to hormone therapy in women with HR-positive, early-stage breast cancer.

Access to generic hormone therapy medicines improves the chances that breast cancer patients will stick with their drug treatment, a new study found.

"We know that hormone therapy for women with hormone receptor-positive breast cancer can reduce recurrence by up to 50%," study leader Dr Dawn Hershman, an associate professor of epidemiology at Columbia University Medical Center in New York City, said in a hospital news release.

"However, work by our group and others has shown that a substantial number of women discontinue treatment before the recommended 5 years or do not take the prescribed dose," she added.

"Our findings suggest that more effort should be made to reduce out-of-pocket costs for these potentially life-saving medications. This is especially important given the rapid increase of expensive oral cancer therapies," explained Hershman, who is also an associate professor of medicine at Columbia's College of Physicians and Surgeons.

Read the complete report on MedlinePlus: http://1.usa.gov/1qnlIJi

Related Videos
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Will Shapiro, vice president of data science, Flatiron Health
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Will Shapiro, vice president of data science, Flatiron Health
Jonathan E. Levitt, Esq, Frier Levitt, LLC
Judy Alberto, MHA, RPh, BCOP, Community Oncology Alliance
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.